# 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography

> **NCT04615156** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eastern Health, Canada** · enrollment: 10000 (estimated)

## Conditions studied

- Solitary Pulmonary Nodule
- Oncology
- 18F-2-fluoro-2-deoxy-D-glucose
- Adverse Event

## Interventions

- **DRUG:** 18F-2-fluoro-2-deoxy-D-glucose

## Key facts

- **NCT ID:** NCT04615156
- **Lead sponsor:** Eastern Health, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-11-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2020-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615156, "18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04615156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*